SPECIAL NOTICE
99 -- Testing of Compounds for IRAK and FLT3 Kinase Binding
- Notice Date
- 10/26/2022 8:17:40 AM
- Notice Type
- Special Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Response Due
- 11/7/2022 9:00:00 AM
- Point of Contact
- Sarah Adan, Phone: 3014805422, Valerie Whipple
- E-Mail Address
-
sarah.adan@nih.gov, valerie.whipple@nih.gov
(sarah.adan@nih.gov, valerie.whipple@nih.gov)
- Description
- THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).� The National Center for Advancing Translational Sciences (NCATS) intends to negotiate on a sole source basis with Eurofins Panlabs Inc. for the Testing of Compounds for IRAK and FLT3 Kinase Binding.� NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS The intended procurement is classified under NAICS code 541380 � Testing Laboratories with a Size Standard of $16.5 million. � REGULATORY AUTHORITY� This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures. Contracts awarded using FAR Part 13�Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6�Competition Requirements. FAR Subpart 13.106-1 (b) Soliciting from a single source provides that: For purchases not exceeding the simplified acquisition threshold, Contracting officers may solicit from one source IF the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name OR industrial mobilization). The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2022-05 dated October 25, 2022. DESCRIPTION OF REQUIREMENT PURPOSE AND OBJECTIVES: The National Center for Advancing Translational Sciences (NCATS) requires the testing of novel small molecule compounds using the KinomeScan binding assay platform. This is for �the testing of thirty (30) novel small molecule compounds for binding to a set of 13 kinase enzymes. This testing will inform on the compounds' abilities to bind key enzyme targets, and will facilitate further optimization and development of these IRAK4 / FLT3 inhibitor compounds as potential treatments for cancers such as AML and MDS. Prior work at NCATS has produced a series of small molecule IRAK4 / FLT3 kinase dual inhibitors, including NCGC00371481 and its structural analogs. Compounds such as �1481 have shown promising results in cellular and mouse models of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Further optimization of the biochemical, physiochemical, and pharmacokinetic properties of these compounds is required, and may eventually produce a clinical candidate that could be used to treat cancers such as MDS and / or AML. In order for a candidate compound to advance into clinical trials, it must display a wide range of acceptable properties. �For this program, compounds must display potent binding to the desired targets: �wild-type IRAK1, IRAK4, and FLT3, as well as all of the clinically-relevant mutant isoforms of FLT3. �Only compounds that bind potently to all of those enzymes can be considered as clinical candidates. � NCATS is currently synthesizing structurally novel analogs of NCGC00371481 that may show improved properties relative to previous analogs. �In order to assess these analogs� abilities to bind their desired targets, these need to be tested for binding activity against the kinase enzymes IRAK1, IRAK4, wild-type FLT3, and a panel of clinically relevant FLT3 mutants. The Contractor shall:� 1.�� �Test thirty (30) novel small molecule compounds for binding to a set of 13 kinase enzymes. a.�� �Test each of the 30 small molecule compounds for binding to a set of 13 kinase enzymes, using the KinomeScan binding assay platform. i.�� �Compounds will be tested in duplicate (n=2) at 11 different concentrations, which will be determined by the Government at the time the compounds are submitted. ii.�� �The 11 different concentrations will be used to generate an IC50 curve. iii.�� �The Government anticipates sending the 30 compounds in three batches of 10 compounds per batch within the period of performance. The schedule of when the batches will be sent is to be determined.� b.�� �Provide three comprehensive reports : one for each batch of 10 compounds, with the results of each of the 10 compounds against the 13 kinase enzymes. DELIVERABLES: The Contractor shall provide the data analysis and report for the contents of the statement of work. The data analysis and report shall be submitted within 60 days after receipt of each batch of compounds, and shall be submitted electronically to the Center�s POC.� CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Eurofins Panlabs Inc. is the only vendor in the marketplace that can provide the services required by NCATS . The intended source is: Eurofins Panlabs Inc.� 6 Research Park Drive,� St Charles, MO 63304 CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice.� A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.� Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by the closing date and time of this announcement and must reference the solicitation number, NCATS-23-000140. Responses must be submitted electronically to Sarah Adan, Contract Specialist, at sarah.adan@nih.gov and Valerie Whipple, Contracting Officer, at valerie.whipple@nih.gov. �U.S. Mail and fax responses will not be accepted. �
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/d9e1996a09c34184a559951db3a15225/view)
- Record
- SN06502831-F 20221028/221026230119 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |